Return to homepagePandemic Pact

Development of a Th1-biased vaccine for SARS-CoV-2

  • Funded by North Carolina Biotechnology Center
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Known Financial Commitments (USD)

    $19,676

  • Funder

    North Carolina Biotechnology Center

  • Principal Investigator

    David Zaharoff

  • Research Location

    United States of America

  • Lead Research Institution

    North Carolina State University

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

This project will test a novel COVID-19 vaccine comprised of inactivated SARS-CoV-2 formulated in a biopolymer solution containing immune modulators.